Efficacy and Safety of Brepocitinib in Cutaneous Sarcoidosis

In the phase 2 portion of the BEACON randomized clinical trial, brepocitinib produced rapid, dose-dependent, and clinically meaningful improvements in CS. As the first randomized, placebo-controlled trial to demonstrate efficacy of a targeted therapy in CS, these findings support selective TYK2/JAK1 inhibition as a potentially promising therapeutic strategy for CS and support ongoing phase 3 evaluation.

Corresponding Author: Misha Rosenbach, MD, Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19066 (misha.rosenbach@pennmedicine.upenn.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.